Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies

Alpha-synuclein is a 15 kDa protein associated with neurodegenerative diseases such as Parkinson disease and multiple-system atrophy where pathological forms of alpha-synuclein aggregate and become neurotoxic. Here we describe the nonclinical program to support a first-in-human (FIH) single ascendin...

Full description

Bibliographic Details

Published in:	mAbs
Main Authors:	Lone Fjord-Larsen, Annemette Thougaard, Karen Malene Wegener, Joan Christiansen, Frank Larsen, Lise Maj Schrøder-Hansen, Marianne Kaarde, Dorte Kornerup Ditlevsen
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-01-01
Subjects:	Alpha-synuclein cerebrospinal fluid monoclonal antibody nonclinical safety pharmacokinetics target engagement
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2021.1994690